<DOC>
	<DOC>NCT00704483</DOC>
	<brief_summary>This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis</brief_summary>
	<brief_title>Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Inclusion criteria Men or women of at least 18 years old. Stable maintenance of renal replacement therapy 3 times per week. Controlled Serum phosphate if under phosphatebinder therapy. Serum phosphate level ≥ 6.0 mg/dL (&gt; 1.9 mmol/L) prior to study treatment initiation. Exclusion criteria Peritoneal dialysis. Parathyroidectomy or transplant scheduled during the study. Uncontrolled hyperparathyroidism History of hemochromatosis or ferritin &gt; 1000 µg/L. Clinically significant GI disorder Unstable medical condition other than Chronic Kidney Disease. Treated with oral iron. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodiafiltration</keyword>
</DOC>